AtriCure to announce second quarter 2026 financial results
AtriCure, Inc. will announce its second quarter 2026 financial results on July 23, 2026, followed by an audio webcast at 4:30 p.m. Eastern Time. The company specializes in surgical treatments for atrial fibrillation and related conditions. Participants can register online for the webcast, and a replay will be available.
*this image is generated using AI for illustrative purposes only.
AtriCure, Inc. will release its second quarter 2026 financial results on Thursday, July 23, 2026. The announcement will provide insights into the company's performance for the quarter, including key financial metrics and operational updates. AtriCure specializes in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management.
The company will host an audio webcast at 4:30 p.m. Eastern Time on July 23, 2026, to discuss its second quarter financial results. Participants interested in listening to the conference call must register online using the provided link. Registration is encouraged more than 15 minutes before the start of the call to ensure access.
A live and replay version of the audio webcast will be available on AtriCure's investor relations website. The webcast will cover details about the company's financial performance and may include guidance or strategic updates. AtriCure's technologies are used by surgeons globally for Afib treatment, reduction of Afib-related complications, and post-operative pain management.
Key Event Details
| Event | Date | Time |
|---|---|---|
| Financial Results Release | July 23, 2026 | Market Open |
| Audio Webcast | July 23, 2026 | 4:30 p.m. ET |
AtriCure's product portfolio includes the Isolator Synergy Ablation System, the first FDA-approved medical device for treating persistent Afib. The company's AtriClip Left Atrial Appendage Exclusion System products are among the most widely sold LAA management devices worldwide. Additionally, its Hybrid AF Therapy offers a minimally invasive solution for long-standing persistent Afib patients.
For more information, investors can visit AtriCure's investor relations website or contact the company's Chief Financial Officer, Angie Wirick, or its Investor Relations representative, Marissa Bych.
How will the upcoming financial results reflect the market adoption of AtriCure's minimally invasive Hybrid AF Therapy?
What strategic updates might be announced regarding the expansion of the Isolator Synergy Ablation System into new international markets?
Could the company provide revised guidance for the full year 2026 based on Q2 performance and current demand trends?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
